TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25554008

Group type: EXPERIMENTAL
Intervention: Pressure-standardized compression (10 kPa)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Force-standardized compression (14 daN)
Number of subjects: 433
Study: 24238630

Group type: EXPERIMENTAL
Intervention: Web-based treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 21336185

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 28
Study: 20144171

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Vaginal misoprostol (50 microg)
Number of subjects: 480
Study: 17885577

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (open-label and double-blind)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 54
Study: 15502058

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Propofol/sufentanil
Number of subjects: 54
Study: 11181092

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9786345

Group type: EXPERIMENTAL
Intervention: Early morning blood collection
Number of subjects: 657
Study: 7874154

Group type: EXPERIMENTAL
Intervention: ATP‐E (0.2 g.kg‐1.day‐1)
Number of subjects: 12
Study: 3282867

Group type: EXPERIMENTAL
Intervention: Sustained action tiaprofenic acid 600 mg once daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sustained release indomethacin 75 mg once daily
Number of subjects: 98
Study: 31811952

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (2-3 sessions combined with daily exercise)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary fiber supplementation (3.5 g plantago ovata per day)
Number of subjects: 50
Study: 31654837

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 28336105

Group type: EXPERIMENTAL
Intervention: Low polyamine diet (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partial polyamine diet (group 2)
Number of subjects: 0
Study: 25351805

Group type: EXPERIMENTAL
Intervention: Soy nuts
Number of subjects: 17

Group type: COMPARATOR
Intervention: Macronutrient-matched control snack
Number of subjects: 17
Study: 23477538

Group type: EXPERIMENTAL
Intervention: Duloxetine (n = 3148)
Number of subjects: 5347

Group type: COMPARATOR
Intervention: Placebo (n = 2199)
Number of subjects: 5347
Study: 21720264

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 855
Study: 19794985

Group type: EXPERIMENTAL
Intervention: Soy-extract isoflavones
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Genistein low-excretors
Number of subjects: 53
Study: 16333546

Group type: COMPARATOR
Intervention: Raw CO2 (group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Heated CO2 (group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Humidified CO2 (group 3)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Heated and humidified CO2 (group 4)
Number of subjects: 44
Study: 15339440

Group type: EXPERIMENTAL
Intervention: Single-application of manipulation
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Union-application of manipulation
Number of subjects: 242
Study: 11168303

Group type: EXPERIMENTAL
Intervention: Dinamap oscillometric device
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sphygmomanometer
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both methods (Dinamap and sphygmomanometer)
Number of subjects: 79
Study: 9579209

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of meglumine antimoniate (MA; 15 mg Sb/kg.day) on 6 days/week for 12 injections.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intralesional administration of meglumine antimoniate (MA; 0.2‐0.8 ml/lesion) every other day for 30 days.
Number of subjects: 80
Study: 8200946

Group type: EXPERIMENTAL
Intervention: Synthetic human CNP‐22 (5 pmol/kg.min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CNP during coinfusion of angiotensin‐II
Number of subjects: 9
Study: 3300518

Group type: EXPERIMENTAL
Intervention: Clonidine (0.0075 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine (0.015 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine (twice a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine (in patients receiving neuroleptic agents)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine (low dose vs high dose)
Number of subjects: 30
Study: 30001903

Group type: EXPERIMENTAL
Intervention: Combined intervention (manual therapy + motor control exercises + inspiratory muscle training)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 51
Study: 27296490

Group type: EXPERIMENTAL
Intervention: 25 mg oral methotrexate weekly
Number of subjects: 43

Group type: COMPARATOR
Intervention: 1 g mycophenolate mofetil twice daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 43
Study: 24497828

Group type: EXPERIMENTAL
Intervention: IL-7 administration (recombinant human IL-7 at 20 µg/kg, three subcutaneous injections)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: IL-7 administration
Number of subjects: 23
Study: 24349532

Group type: EXPERIMENTAL
Intervention: IL‐18 ‐607A/C polymorphism (A/A homozygotes) among alcohol consumers
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: IL‐18 ‐137 polymorphism (G/C heterozygotes)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Exposure to oral cancer-related environmental risk factors (areca, alcohol, tobacco)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: IL‐18 ‐137 G/C alleles
Number of subjects: 1126
Study: 20934561

Group type: EXPERIMENTAL
Intervention: silent MI
Number of subjects: 5733

Group type: EXPERIMENTAL
Intervention: HxMI
Number of subjects: 5733

Group type: COMPARATOR
Intervention: no prior MI
Number of subjects: 5733
Study: 18237588

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) at cuff pressures of 300 mm Hg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment at cuff pressures of 75 mm Hg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) and Sham treatment
Number of subjects: 21
Study: 16901294

Group type: EXPERIMENTAL
Intervention: Health screening intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study: 12627927

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) for outpatients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated heparin for inpatients
Number of subjects: 100
Study: 11802676

Group type: EXPERIMENTAL
Intervention: Temperature Biofeedback (N = 81)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: EMG Biofeedback (N = 74)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Normal Temperature Biofeedback (N = 46)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Behavioral Control Procedure (frontalis EMG biofeedback)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Nifedipine-XL
Number of subjects: 313

Group type: COMPARATOR
Intervention: Medication Placebo
Number of subjects: 313
Study: 9507235

Group type: EXPERIMENTAL
Intervention: 8:0 + 10:0 diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 12:0 diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 14:0 diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 16:0 diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 18:0 diet
Number of subjects: 36
Study: 7845799

Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to low with medium speed of response
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to medium with fast speed of response
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rate augmentation factor set to high with fast speed of response
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fast response time
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rate augmentation factor
Number of subjects: 9
Study: 3132056

Group type: EXPERIMENTAL
Intervention: Experimental group (Datex ABM device for monitoring)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (video monitor screen turned off)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 31814476

Group type: EXPERIMENTAL
Intervention: Self-management support system including a home-BP monitor, self-reports, and BP measurements every evening for eight weeks
Number of subjects: 900

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Self-management support system
Number of subjects: 900
Study: 29631810

Group type: EXPERIMENTAL
Intervention: sorafenib plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle)
Number of subjects: 206

Group type: COMPARATOR
Intervention: sorafenib monotherapy (400 mg orally twice daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: sorafenib plus hepatic arterial infusion chemotherapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: sorafenib monotherapy
Number of subjects: 206
Study: 28854967

Group type: EXPERIMENTAL
Intervention: Integrated securement-dressing
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Suture-less securement device
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane dressing and suture)
Number of subjects: 48
Study: 26451086

Group type: COMPARATOR
Intervention: Generic MT 5 mg chewable tablets
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Branded Singulair(®) pediatric 5 mg chewable tablets
Number of subjects: 32
Study: 24553281

Group type: EXPERIMENTAL
Intervention: 10 percent CPP-ACP cream
Number of subjects: 191

Group type: COMPARATOR
Intervention: No product (comparison group)
Number of subjects: 191
Study: 21047923

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18808753

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17154733

Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dialectical behavior therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Modified psychodynamic supportive psychotherapy
Number of subjects: 90
Study: 14714578

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 62

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 62
Study: 11060420

Group type: EXPERIMENTAL
Intervention: Class 1 Elastic Compression Stockings (pressure at the ankle 10 to 15 mmHg)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo Stockings (pressure at the ankle 3 to 6 mmHg)
Number of subjects: 341
Study: 8941023

Group type: EXPERIMENTAL
Intervention: Standardized meal consumption
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Infusion of rt-PA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Abstaining from food
Number of subjects: 8
Study: 1357924

Group type: EXPERIMENTAL
Intervention: Protopam chloride (1,000 mg intravenously)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protopam chloride (oral and parenteral administration)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protopam chloride with electrical stimulation of the spinal cord
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protopam chloride without electrical stimulation of the spinal cord
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protopam chloride (large doses)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Protopam chloride
Number of subjects: 61
Study: 30857448

Group type: EXPERIMENTAL
Intervention: Oral squamous cell carcinoma (OSCC) patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral leukoplakia (OL) patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study: 30094810

Group type: EXPERIMENTAL
Intervention: Individually configured wheelchair and skin protection cushion
Number of subjects: 258

Group type: COMPARATOR
Intervention: Facility‐provided wheelchair and skin protection cushion
Number of subjects: 258
Study: 26938218

Group type: EXPERIMENTAL
Intervention: CPS1 gene expression levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNPs rs10206976 and rs12613336
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene-metabolite interaction network analysis
Number of subjects: 0
Study: 24373019

Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1 mg twice daily (group A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Propiverine 20 mg once daily (group B)
Number of subjects: 162
Study: 23086050

Group type: EXPERIMENTAL
Intervention: Elaboration on a given case
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Develop their own case
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elaborate on a self‐developed case
Number of subjects: 0
Study: 22406705

Group type: EXPERIMENTAL
Intervention: Lycopene 8 mg/day for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study: 18077928

Group type: EXPERIMENTAL
Intervention: gemifloxacin 320 mg/tablet (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: factive 320 mg/tablet (reference product)
Number of subjects: 24
Study: 15643181

Group type: EXPERIMENTAL
Intervention: BCG (81 mg, 6 weekly instillations)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Epirubicin (50 mg, 8 weekly instillations)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 168

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: BCG and Epirubicin
Number of subjects: 168
Study: 11862370

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10194744

Group type: EXPERIMENTAL
Intervention: AR-CARES program
Number of subjects: 0
Study: 7477743

Group type: EXPERIMENTAL
Intervention: Citicoline (CDP-choline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2105638

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 1,200 mg/d for 16 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (observation without changes in prescription)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SCG group (responders)
Number of subjects: 30
Study: 6975168

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Co-tri-famole (80 mg trimethoprim and 400 mg sulfamoxole)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cotrimoxazole and Co-tri-famole
Number of subjects: 10
Study: 31665467

Group type: EXPERIMENTAL
Intervention: Consolidative radiotherapy (more than 50 Gy)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Palliative radiotherapy (less than 50 Gy)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Metastasectomy for disease consolidation
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Radiotherapy for disease consolidation
Number of subjects: 228
Study: 31487442

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 months, 3 sessions per week, 1 hour each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (after 2 months post-intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (after 2 months post-intervention)
Number of subjects: 60
Study: 28276980

Group type: EXPERIMENTAL
Intervention: Caffeine cravings (induced via abstinence, cue exposure, and imagery)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition (no caffeine cravings)
Number of subjects: 55
Study: 23919432

Group type: EXPERIMENTAL
Intervention: Subtenon block
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intravenous fentanyl (1 μg·kg(‐1))
Number of subjects: 63
Study: 23181640

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (HAase) injection (20,000 turbidity-reducing units)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 160
Study: 19261295

Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride, 20 mg/kg/d for 10 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17684167

Group type: EXPERIMENTAL
Intervention: Promotora diabetes intervention (culturally specific participative group education, telephone contact, and follow-up with health behavior change postcards)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 15120808

Group type: EXPERIMENTAL
Intervention: Predischarge carvedilol initiation
Number of subjects: 363

Group type: COMPARATOR
Intervention: Postdischarge initiation of beta-blockade
Number of subjects: 363
Study: 11687357

Group type: EXPERIMENTAL
Intervention: 3‐piece acrylic IOL
Number of subjects: 87

Group type: COMPARATOR
Intervention: PMMA IOL
Number of subjects: 87

Group type: COMPARATOR
Intervention: Silicone IOL
Number of subjects: 87
Study: 9153532

Group type: EXPERIMENTAL
Intervention: Homozygous form of the 6-base intronic insertion in endoglin gene
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (202 controls)
Number of subjects: 103
Study: 8265301

Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) at a dose of 6 mumol/kg body weight
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 517
Study: 3666079

Group type: EXPERIMENTAL
Intervention: Chewing at high frequencies (metronome set at 160 beats per minute)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chewing at low frequencies (metronome set at 46 beats per minute)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chewing at high frequencies (metronome set at 100 beats per minute)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All chewing rates
Number of subjects: 9
Study: 31854465

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30887496

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 28363133

Group type: EXPERIMENTAL
Intervention: Step Aerobics (SA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stability Ball (SB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (Ceramic Class)
Number of subjects: 42
Study: 26079196

Group type: EXPERIMENTAL
Intervention: 16-week Doing Me! intervention (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control (n = 30)
Number of subjects: 60
Study: 23648800

Group type: EXPERIMENTAL
Intervention: Plasma levels of total AGEs, LWM‐AGEs, and HWM‐AGEs; cathepsin B activity in plasma and neutrophils
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: HWM‐AGEs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LMW‐AGEs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Increasing levels of HWM‐AGEs and LMW‐AGEs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Plasma level of LMW‐AGEs
Number of subjects: 102
Study: 21357906

Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 25 mg/d for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Number of subjects: 60
Study: 19220069

Group type: EXPERIMENTAL
Intervention: Community pharmacist-led intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 174
Study: 17267370

Group type: EXPERIMENTAL
Intervention: Telephone-based support groups (telesupport)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 103
Study: 15018279

Group type: EXPERIMENTAL
Intervention: Intermittent exposure to bright light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular exposure to lower light levels and darkness
Number of subjects: 0
Study: 11227205

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish applied every 8 weeks for 21 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo varnish applied every 8 weeks for 21 months
Number of subjects: 33
Study: 9039155

Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation (1500 mg of calcium per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8341042

Group type: EXPERIMENTAL
Intervention: .85 g/kg alcohol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control beverage (ginger ale)
Number of subjects: 4
Study: 3669071

Group type: EXPERIMENTAL
Intervention: Verbal commitment (parents asked for a verbal promise)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment choice (parents allowed to choose between two antibiotics)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment choice (parents not allowed to choose)
Number of subjects: 89
Study: 30430343

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control
Number of subjects: 117
Study: 28821290

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.06% Chlorhexidine mouthwash
Number of subjects: 0